Delivery Order SPE2DB22D1106-SPE2DB25FFGK6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Micardis HCT 40-12.5 mg tablet unit dose packages (30 count). This competitive award, valued at $4,145.28 with firm fixed pricing, is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract contains no set-aside designation and represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Micardis HCT 40-12.5 mg tablets (unit dose, 30 count) with a contract value of $3,124.61. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,044.82 to supply Micardis HCT 80-25 mg tablet unit dose packages (30 count) with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a $1,108.80 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Micardis HCT 80-12.5 mg tablets in unit dose packaging (30 count). This competitively awarded, firm fixed-price contract has an ultimate completion date of August 29, 2025, with performance conducted at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition in the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-12.5 mg tablets (30-unit dose) valued at $4,139.85. This competitive, firm fixed-price contract was awarded on August 27, 2025, with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, PA, where AmerisourceBergen maintains its corporate headquarters. No set-aside designation was applied to this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,503.31 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30-count) on August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August...
- The Defense Logistics Agency awarded a delivery order valued at $3,631.02 to AmerisourceBergen Drug Corp for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) on August 11, 2025, with completion due by August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen Drug Corp's larger prime indefinite delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,163.02 to AmerisourceBergen Drug Corp for the supply of MICARDIS HCT 40-12.5 mg tablets in unit dose packaging (30 count) on September 2, 2025, with completion expected by September 3, 2025. This contract was awarded on a non-competitive, firm fixed-price basis and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through...
- This delivery order, awarded on August 28, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30-count) with a ceiling value of $1,742.70 under firm fixed price terms. The contract is non-set-aside and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026. The...
- This delivery order, awarded on August 27, 2025, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is for the supply of Micardis HCT 40-12.5 mg tablets in unit dose packaging (30 count) with a ceiling value of $9,314.20. The contract utilizes firm fixed pricing with an ultimate completion date of August 28, 2025, and was competitively awarded by the Defense Logistics Agency without any set-aside designation. This delivery order...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFGK6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Micardis HCT 80-25 mg tablets in unit dose packaging (30-count). This competitively awarded, firm fixed price delivery order carries a ceiling value of $3,758.67 and is scheduled for completion by September 3, 2025. The contract represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support platform for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract performance demonstrates capability to fulfill diverse pharmaceutical requirements through open competition across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 9/2/25 |